Gulf Coast Clinical Research

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• High blood pressure2 trials
• Asthma1 trial
• Chronic kidney disease1 trial
• COPD1 trial
• Coronary artery disease1 trial
• Diabetic eye disease1 trial
• Graves' disease and hyperthyroidism1 trial
• Peripheral artery disease1 trial

Phase

• Phase 24 trials
• Phase 2/31 trial
• Phase 31 trial

Status

• Completed3 trials
• Active, not recruiting2 trials
• Recruiting2 trials

Lead sponsor

• Mineralys Therapeutics Inc.2 trials
• Uniquity One (UNI)2 trials
• Biogen1 trial
• CSL Behring1 trial
• Optain Health1 trial

Running trials

• Recruiting

  A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old

  NCT07722546· Phase 2· Biogen· Source

  Contact: Anjani Pandya (principal investigator)

• Active, not recruiting

  A Study to Evaluate Solrikitug in Participants With COPD (ZION)

  NCT06496620· Phase 2· Uniquity One (UNI)· Source

• Recruiting

  Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

  NCT05485961· Phase 2/3· CSL Behring· Source

  Contact: Trial Registration Coordinator

• Active, not recruiting

  Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension

  NCT05968430· Phase 3· Mineralys Therapeutics Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Chronic kidney disease1 recruiting
• Coronary artery disease1 recruiting
• Graves' disease and hyperthyroidism1 recruiting
• Peripheral artery disease1 recruiting

Closed trials

• Completed

  A Study to Evaluate Solriktug in Adult Participants With Asthma

  NCT06496607· Phase 2· Uniquity One (UNI)· Source

• Completed

  OPTDR01 Feasibility for Automated Diabetic Retinopathy Detection

  NCT06343350· Optain Health· Source

• Completed

  A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen

  NCT05769608· Phase 2· Mineralys Therapeutics Inc.· Source